A Phase I Clinical Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Ganetespib (Primary) ; Paclitaxel; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
- 05 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.